TDMS Study 05197-12 Pathology Tables
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
FINAL#1, REVISION #1
Facility: Battelle Northwest
Chemical CAS #: 111-76-0002
Lock Date: 11/08/96
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 6 3 5 4
Moribund Sacrifice 14 16 12 10
Accidently Killed 1
Survivors
Terminal Sacrifice 29 31 33 36
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (49) (50) (50)
Epithelium, Hyperplasia 1 (2%)
Intestine Large, Colon (49) (50) (48) (50)
Inflammation 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Intestine Large, Cecum (49) (50) (47) (48)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Duodenum (45) (49) (47) (47)
Inflammation 2 (4%)
Necrosis 1 (2%)
Epithelium, Hyperplasia 1 (2%) 2 (4%) 2 (4%)
Intestine Small, Jejunum (46) (49) (47) (48)
Inflammation 1 (2%)
Necrosis 1 (2%)
Intestine Small, Ileum (46) (50) (47) (48)
Peyer's Patch, Hyperplasia 1 (2%)
Liver (50) (50) (49) (50)
Angiectasis 1 (2%) 2 (4%)
Basophilic Focus 1 (2%) 1 (2%)
Clear Cell Focus 2 (4%) 1 (2%) 1 (2%)
Degeneration, Fatty 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Eosinophilic Focus 10 (20%) 6 (12%) 10 (20%) 5 (10%)
Hematopoietic Cell Proliferation 5 (10%) 7 (14%) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Infarct 1 (2%)
Inflammation 3 (6%) 5 (10%) 4 (8%) 4 (8%)
Necrosis 2 (4%) 8 (16%) 7 (14%) 3 (6%)
Thrombosis 1 (2%)
Bile Duct, Cyst 1 (2%)
Endothelial Cell, Hyperplasia 1 (2%)
Kupffer Cell, Pigmentation, Hemosiderin 5 (10%) 25 (51%) 44 (88%)
Mesentery (10) (4) (5) (9)
Fat, Necrosis 7 (70%) 3 (75%) 4 (80%) 9 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Pancreas (49) (50) (49) (50)
Atrophy 6 (12%) 4 (8%) 2 (4%) 8 (16%)
Cytoplasmic Alteration 1 (2%) 2 (4%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation 3 (6%)
Duct, Cyst 1 (2%) 1 (2%)
Duct, Inflammation 1 (2%)
Stomach, Forestomach (50) (50) (49) (50)
Cyst Epithelial Inclusion 1 (2%)
Erosion 1 (2%)
Ulcer 1 (2%) 7 (14%) 13 (27%) 22 (44%)
Epithelium, Hyperplasia 6 (12%) 27 (54%) 42 (86%) 44 (88%)
Stomach, Glandular (48) (50) (49) (49)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (2%)
Ulcer 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Epithelium, Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Tongue (1) (1)
Epithelium, Hyperplasia 1 (100%)
Tooth (1)
Inflammation 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1) (2)
Inflammation 1 (50%)
Mineralization 1 (100%)
Heart (50) (50) (50) (50)
Cardiomyopathy 46 (92%) 45 (90%) 44 (88%) 45 (90%)
Mineralization 1 (2%)
Artery, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Amyloid Deposition 1 (2%)
Degeneration, Cystic 2 (4%)
Hematopoietic Cell Proliferation 1 (2%) 2 (4%)
Hyperplasia 1 (2%)
Hypertrophy 3 (6%) 2 (4%) 6 (12%) 5 (10%)
Capsule, Hyperplasia 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Hyperplasia 1 (2%) 3 (6%) 3 (6%) 2 (4%)
Islets, Pancreatic (50) (50) (49) (50)
Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Pituitary Gland (50) (49) (48) (49)
Pars Distalis, Angiectasis 1 (2%) 4 (8%)
Pars Distalis, Hyperplasia 15 (30%) 15 (31%) 16 (33%) 20 (41%)
Pars Intermedia, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Inflammation 1 (2%)
Follicle, Cyst 1 (2%)
Follicular Cell, Hyperplasia 11 (22%) 8 (16%) 11 (22%) 11 (22%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (49) (49)
Angiectasis 2 (4%) 2 (4%) 1 (2%)
Atrophy 1 (2%) 2 (4%) 2 (4%) 1 (2%)
Cyst 11 (22%) 12 (24%) 19 (39%) 16 (33%)
Degeneration, Fatty 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Inflammation 1 (2%) 1 (2%)
Thrombosis 1 (2%) 2 (4%)
Corpus Luteum, Hyperplasia 1 (2%)
Germinal Epithelium, Hyperplasia 1 (2%) 1 (2%)
Interstitial Cell, Hyperplasia 1 (2%)
Uterus (50) (50) (49) (50)
Adenomyosis 1 (2%)
Angiectasis 2 (4%) 3 (6%) 1 (2%)
Hydrometra 2 (4%) 2 (4%) 1 (2%) 3 (6%)
Hyperplasia, Cystic 2 (4%) 2 (4%) 6 (12%)
Inflammation 1 (2%)
Lymphangiectasis 1 (2%)
Thrombosis 1 (2%)
Arteriole, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Fibrosis 1 (2%)
Hyperplasia 2 (4%) 4 (8%) 2 (4%) 3 (6%)
Hyperplasia, Megakaryocyte 1 (2%)
Lymph Node (4) (7) (6) (1)
Angiectasis 1 (25%) 1 (14%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia 1 (25%)
Iliac, Hyperplasia 1 (25%)
Pancreatic, Hyperplasia 1 (14%)
Lymph Node, Bronchial (41) (39) (41) (37)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 1 (2%) 6 (15%) 4 (10%)
Hyperplasia, Histiocytic 1 (3%)
Lymph Node, Mandibular (37) (38) (40) (38)
Hyperplasia 1 (3%) 2 (5%) 2 (5%) 1 (3%)
Lymph Node, Mesenteric (47) (48) (49) (50)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%)
Hyperplasia 1 (2%) 2 (4%) 3 (6%) 3 (6%)
Lymph Node, Mediastinal (31) (40) (38) (34)
Hyperplasia 2 (6%) 2 (5%) 5 (13%)
Hyperplasia, Lymphoid 1 (3%)
Spleen (50) (50) (49) (50)
Hematopoietic Cell Proliferation 24 (48%) 29 (58%) 32 (65%) 35 (70%)
Hyperplasia, Lymphoid 6 (12%) 15 (30%) 12 (24%) 10 (20%)
Pigmentation, Hemosiderin 39 (78%) 44 (88%) 46 (94%) 48 (96%)
Thymus (46) (41) (46) (48)
Atrophy 1 (2%) 2 (5%)
Hyperplasia, Lymphoid 1 (2%) 2 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Hyperplasia 2 (4%) 2 (4%) 1 (2%) 2 (4%)
Skin (50) (50) (50) (50)
Atrophy 1 (2%)
Inflammation, Chronic Active 1 (2%)
Necrosis 1 (2%)
Pinna, Inflammation, Chronic 1 (2%)
Subcutaneous Tissue, Edema 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Arthrosis 1 (2%)
Fibrous Osteodystrophy 22 (44%) 28 (56%) 25 (50%) 21 (42%)
Maxilla, Fracture 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Cyst Epithelial Inclusion 1 (2%)
Hemorrhage 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Necrosis 1 (2%)
Meninges, Infiltration Cellular, Mononuclear
Cell 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (49)
Inflammation, Suppurative 1 (2%) 3 (6%) 1 (2%)
Squamous Epithelium, Hyperplasia 2 (4%) 8 (16%) 3 (6%) 5 (10%)
Lung (50) (50) (50) (50)
Hemorrhage 10 (20%) 2 (4%) 6 (12%) 6 (12%)
Infiltration Cellular, Histiocyte 3 (6%) 2 (4%) 3 (6%) 2 (4%)
Inflammation 1 (2%)
Metaplasia, Osseous 1 (2%)
Pigmentation, Hemosiderin 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (4%) 2 (4%) 2 (4%)
Mediastinum, Inflammation 1 (2%)
Perivascular, Inflammation 2 (4%)
Nose (50) (50) (49) (50)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Inflammation, Suppurative 2 (4%) 3 (6%) 1 (2%)
Olfactory Epithelium, Atrophy 2 (4%) 4 (8%) 2 (4%) 4 (8%)
Olfactory Epithelium, Degeneration, Hyaline 6 (12%) 14 (28%) 11 (22%) 12 (24%)
Olfactory Epithelium, Metaplasia 1 (2%) 1 (2%)
Respiratory Epithelium, Degeneration, Hyaline 17 (34%) 35 (70%) 26 (53%) 23 (46%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (4)
Degeneration 1 (25%)
Cornea, Inflammation, Chronic 1 (100%) 3 (75%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Glomerulosclerosis 7 (14%) 2 (4%) 8 (16%) 8 (16%)
Inflammation, Chronic Active 1 (2%)
Metaplasia, Osseous 1 (2%) 1 (2%) 3 (6%) 4 (8%)
Nephropathy 34 (68%) 39 (78%) 38 (78%) 33 (66%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Pigmentation, Hemosiderin 1 (2%) 1 (2%)
Renal Tubule, Degeneration 1 (2%)
Renal Tubule, Hyperplasia 1 (2%)
Renal Tubule, Mineralization 1 (2%)
Urinary Bladder (47) (49) (48) (50)
Inflammation 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 8 13 10
Natural Death 4 3 10 14
Survivors
Terminal Sacrifice 39 39 27 26
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (45) (40) (35)
Degeneration, Hyaline 1 (2%)
Inflammation 1 (2%)
Intestine Small, Duodenum (49) (48) (44) (41)
Inflammation 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Peyer's Patch, Hyperplasia 1 (2%)
Intestine Small, Jejunum (48) (47) (43) (38)
Peyer's Patch, Hyperplasia 1 (2%) 1 (3%)
Intestine Small, Ileum (48) (47) (43) (39)
Inflammation 1 (2%)
Peyer's Patch, Hyperplasia 1 (2%) 1 (2%)
Liver (50) (50) (49) (49)
Angiectasis 1 (2%)
Basophilic Focus 1 (2%) 3 (6%)
Clear Cell Focus 4 (8%) 5 (10%) 3 (6%)
Degeneration, Fatty 1 (2%) 2 (4%) 4 (8%)
Eosinophilic Focus 14 (28%) 10 (20%) 18 (37%) 12 (24%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%)
Infarct 1 (2%)
Inflammation 6 (12%) 3 (6%) 6 (12%) 6 (12%)
Karyomegaly 2 (4%) 1 (2%)
Necrosis 6 (12%) 2 (4%) 7 (14%) 9 (18%)
Bile Duct, Cyst 1 (2%) 1 (2%)
Kupffer Cell, Pigmentation, Hemosiderin 8 (16%) 30 (61%)
Oval Cell, Hyperplasia 1 (2%) 1 (2%) 2 (4%) 3 (6%)
Mesentery (5) (3) (3) (1)
Angiectasis 1 (33%)
Fat, Necrosis 5 (100%) 2 (67%) 2 (67%)
Pancreas (50) (50) (47) (47)
Atrophy 10 (20%) 4 (8%) 2 (4%) 4 (9%)
Cytoplasmic Alteration 1 (2%) 1 (2%)
Degeneration, Hyaline 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation 1 (2%)
Duct, Cyst 1 (2%)
Salivary Glands (50) (50) (48) (50)
Inflammation 1 (2%) 1 (2%) 1 (2%)
Stomach, Forestomach (50) (50) (49) (48)
Cyst 1 (2%)
Hyperplasia 1 (2%)
Mineralization 1 (2%)
Ulcer 1 (2%) 2 (4%) 9 (18%) 3 (6%)
Epithelium, Hyperplasia 1 (2%) 7 (14%) 16 (33%) 21 (44%)
Stomach, Glandular (50) (50) (46) (47)
Degeneration, Hyaline 1 (2%)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Ulcer 1 (2%) 2 (4%)
Epithelium, Hyperplasia 4 (9%) 1 (2%)
Tooth (4)
Malformation 4 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 47 (94%) 48 (96%) 47 (94%) 47 (94%)
Artery, Inflammation 1 (2%)
Atrium, Thrombosis 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Degeneration, Cystic 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hyperplasia 5 (10%) 9 (18%) 9 (18%) 9 (18%)
Hypertrophy 38 (76%) 28 (56%) 27 (55%) 27 (54%)
Capsule, Hyperplasia 2 (4%) 3 (6%)
Adrenal Medulla (49) (50) (49) (49)
Hyperplasia 1 (2%) 2 (4%) 3 (6%)
Islets, Pancreatic (50) (50) (47) (46)
Hyperplasia 6 (12%) 3 (6%) 2 (4%)
Inflammation 1 (2%)
Parathyroid Gland (26) (29) (26) (31)
Cyst 1 (3%)
Pituitary Gland (49) (49) (46) (48)
Hemorrhage 1 (2%)
Pars Distalis, Cyst 1 (2%)
Pars Distalis, Hyperplasia 5 (10%) 1 (2%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thyroid Gland (50) (48) (49) (50)
Follicular Cell, Hyperplasia 5 (10%) 8 (17%) 6 (12%) 5 (10%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49) (50)
Granuloma Sperm 1 (2%)
Hyperplasia 1 (2%)
Inflammation 4 (8%) 4 (8%) 1 (2%) 4 (8%)
Inflammation, Granulomatous 1 (2%)
Penis (1)
Inflammation 1 (100%)
Preputial Gland (49) (49) (49) (49)
Ectasia 1 (2%) 1 (2%) 1 (2%)
Inflammation 2 (4%) 7 (14%) 6 (12%) 8 (16%)
Prostate (49) (49) (48) (45)
Inflammation 2 (4%) 3 (6%) 4 (9%)
Epithelium, Hyperplasia 1 (2%) 1 (2%)
Seminal Vesicle (50) (49) (46) (46)
Inflammation 1 (2%) 2 (4%) 3 (7%)
Testes (50) (50) (49) (50)
Atrophy 5 (10%) 4 (8%) 6 (12%) 4 (8%)
Mineralization 3 (6%)
Interstitial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Fibrosis 1 (2%)
Hyperplasia 1 (2%) 9 (18%) 5 (10%)
Thrombosis 1 (2%)
Lymph Node (2) (1) (1)
Renal, Hyperplasia 1 (100%)
Lymph Node, Bronchial (38) (35) (33) (35)
Hyperplasia 2 (5%) 1 (3%)
Lymph Node, Mandibular (24) (26) (32) (25)
Hyperplasia 1 (4%) 1 (3%) 1 (4%)
Lymph Node, Mesenteric (50) (50) (47) (43)
Amyloid Deposition 1 (2%)
Angiectasis 2 (4%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hematopoietic Cell Proliferation 1 (2%) 3 (6%) 1 (2%)
Hyperplasia 7 (14%) 7 (14%) 4 (9%) 4 (9%)
Spleen (50) (50) (48) (49)
Hematopoietic Cell Proliferation 12 (24%) 11 (22%) 26 (54%) 42 (86%)
Hyperplasia, Lymphoid 5 (10%) 8 (16%) 3 (6%) 1 (2%)
Pigmentation, Hemosiderin 6 (12%) 45 (94%) 44 (90%)
Thymus (43) (43) (36) (37)
Atrophy 1 (2%) 1 (2%) 1 (3%) 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (49) (50)
Granuloma 1 (2%)
Inflammation 1 (2%)
Pigmentation, Melanin 1 (2%)
Prepuce, Hyperplasia 1 (2%) 2 (4%)
Prepuce, Inflammation, Chronic Active 2 (4%) 3 (6%) 13 (27%) 8 (16%)
Prepuce, Ulcer 3 (6%) 11 (22%) 8 (16%)
Subcutaneous Tissue, Inflammation,
Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrous Osteodystrophy 1 (2%) 4 (8%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Inflammation, Chronic 1 (2%)
Necrosis 1 (2%)
Vacuolization Cytoplasmic 1 (2%) 1 (2%)
Meninges, Infiltration Cellular, Mononuclear
Cell 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (48) (49)
Inflammation, Suppurative 1 (2%)
Squamous Epithelium, Hyperplasia 3 (6%)
Lung (50) (50) (49) (50)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hemorrhage 5 (10%) 5 (10%) 5 (10%) 3 (6%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Infiltration Cellular, Histiocyte 6 (12%) 1 (2%) 4 (8%) 4 (8%)
Inflammation, Chronic 1 (2%) 1 (2%)
Pigmentation, Hemosiderin 1 (2%)
Alveolar Epithelium, Hyperplasia 6 (12%) 1 (2%) 2 (4%) 4 (8%)
Artery, Inflammation 1 (2%)
Nose (50) (50) (48) (48)
Inflammation, Suppurative 2 (4%) 6 (12%) 2 (4%) 2 (4%)
Polyp, Inflammatory 1 (2%) 1 (2%)
Glands, Hyperplasia 1 (2%)
Olfactory Epithelium, Atrophy 4 (8%) 4 (8%) 3 (6%)
Olfactory Epithelium, Degeneration, Hyaline 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Respiratory Epithelium, Degeneration, Hyaline 4 (8%) 10 (20%) 5 (10%) 5 (10%)
Respiratory Epithelium, Metaplasia, Squamous 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Inflammation, Granulomatous 1 (100%)
Eye (1) (1)
Cornea, Inflammation, Chronic 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (47) (50)
Glomerulosclerosis 4 (8%) 4 (8%) 11 (23%) 9 (18%)
Hydronephrosis 1 (2%) 6 (13%) 5 (10%)
Inflammation 1 (2%)
Inflammation, Chronic Active 1 (2%) 2 (4%) 4 (8%)
Metaplasia, Osseous 2 (4%)
Mineralization 1 (2%) 2 (4%)
Nephropathy 48 (96%) 45 (90%) 40 (85%) 37 (74%)
Capsule, Inflammation 1 (2%)
Cortex, Cyst 4 (8%) 1 (2%) 6 (12%)
Pelvis, Inflammation, Chronic Active 1 (2%) 1 (2%)
Renal Tubule, Hyperplasia 2 (4%) 2 (4%) 1 (2%)
Renal Tubule, Mineralization 4 (8%) 2 (4%) 3 (6%) 2 (4%)
Renal Tubule, Necrosis 1 (2%) 1 (2%)
Renal Tubule, Pigmentation 3 (6%)
Urinary Bladder (50) (50) (46) (45)
Inflammation 2 (4%) 5 (11%) 4 (9%)
Transitional Epithelium, Hyperplasia 2 (4%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Transitional Epithelium, Ulcer 1 (2%) 4 (9%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------